Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty

Trial Profile

A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDT 10013 (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 26 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint have been changed to PK and AR parameters. Treatment table has also been amended to include only one arm.
    • 26 Feb 2016 Planned number of patients changed from 144 to 32, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top